Q-omics provides the consensus-scored AMER3 profile across patient tissues and cancer cell-line models. AMER3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AMER3 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, AMER3 RNA expression shows 12,041 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, THCA, and GBM as cancer lineages where AMER3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMER3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMER3 survival associations across molecular data types. AMER3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMER3 RNA expression–survival associations across cancer types. High AMER3 expression shows unfavorable associations in ACC, KIRC, LUSC and UVM, but favorable associations in LGG and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AMER3 RNA expression.
This table summarizes AMER3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for AMER3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMER3 shows lower tumor expression in THCA, READ, STAD and COAD and higher tumor expression in HNSC and KICH. The THCA box plot shows higher AMER3 RNA expression in normal versus tumor tissue (log2 FC = −0.094, t-test p < 0.001).
This table shows molecular features associated with AMER3 in patient tissues and cancer cell lines. In patient samples, AMER3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, AMER3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
